Liberty One Investment Management LLC Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Liberty One Investment Management LLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,143 shares of the medical research company’s stock after purchasing an additional 143 shares during the quarter. Liberty One Investment Management LLC’s holdings in IQVIA were worth $618,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA during the third quarter worth approximately $147,683,000. JPMorgan Chase & Co. raised its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Finally, 1832 Asset Management L.P. increased its holdings in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research reports. Bank of America lowered their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Truist Financial decreased their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Robert W. Baird lowered their price target on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Trading Down 0.2 %

NYSE IQV opened at $197.25 on Friday. The company’s fifty day moving average price is $200.09 and its two-hundred day moving average price is $221.29. The company has a market capitalization of $35.80 billion, a price-to-earnings ratio of 25.89, a price-to-earnings-growth ratio of 2.09 and a beta of 1.48. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.